Komori
Susmed (4263) · InitiativeAdvanced

Tokyo Stock Exchange Mothers listing and financing through a public offering

First written in FY2022-Q2. 12 of 13 entries say "Advanced", first in FY2022-Q3. Latest entry: FY2026-H1.

13entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2022-Q2 – FY2026-H12022: 420222023: 420232024: 320242025: 120252026: 1
Same theme, other companies
Tokyo Stock Exchange Mothers Listing and Public OfferingA theme 61 companies write about · 0 as a headwind · 61 as a tailwind

The whole theme swung hardest in 2022: 12 of 45 companies on the "Worse" side.

17 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 61 companies compared. The sentences above are computed from all 61.
Full recordFilings, disclosures and news, newest first
  1. FY2026-H1AdvancedAnnual report

    「16 October 2025 (Note) 1 37,700 16,860,400 16,286 115,513 16,286 5,457,676 1 July 2025–31 December 2025 (Note) 2 7,700 16,868,100 1,590 117,104 1,590 5,459,266」

    During the current interim accounting period, 37,700 shares were issued as restricted stock compensation, and the number of shares increased by 7,700 through the exercise of stock acquisition rights.
  2. FY2025-H1AdvancedAnnual report

    「23 October 2024」

    The company issued 53,600 new shares as restricted stock compensation, increasing share capital and capital reserves. Although this differed from the funds raised at the time of listing, capital continued to increase through share issuances.
  3. FY2024AdvancedAnnual report

    「Funds increased as a result of financing activities amounted to ¥37.372 million (proceeds of ¥62.362 million in the previous fiscal year). This was primarily attributable to proceeds of ¥37.380 million from the issuance of new shares and other items.」

    During the fiscal year, new shares were issued through the exercise of stock acquisition rights and as restricted stock compensation, and proceeds of ¥37.380 million from the issuance of shares were recognized.
  4. FY2024-Q3AdvancedAnnual report

    「During the cumulative third quarter of the current fiscal year, stock acquisition rights were exercised, increasing both share capital and capital surplus by ¥13.546 million.」

    The exercise of stock acquisition rights during the cumulative third quarter of the current fiscal year increased both share capital and capital surplus by ¥13.546 million.
  5. FY2024-Q2AdvancedAnnual report

    「During the cumulative second quarter of the current fiscal year, stock acquisition rights were exercised, increasing both share capital and capital surplus by ¥7.661 million.」

    The exercise of stock acquisition rights during the cumulative second quarter of the current fiscal year increased both share capital and capital surplus by ¥7.661 million.
  6. FY2024-Q1AdvancedAnnual report

    「This reflected an increase of ¥5.637 million each in share capital and capital surplus through the exercise of stock options, while stock acquisition rights increased by ¥2.423 million,」

    Stock options were exercised during the cumulative first quarter of the current fiscal year, increasing both share capital and capital surplus by ¥5.637 million.
  7. FY2023AdvancedAnnual report

    「Proceeds from the issuance of new shares upon exercise of stock acquisition rights: ¥61.562 million」

    New shares were issued through the exercise of stock acquisition rights, resulting in an increase of ¥61.562 million in cash from financing activities during the fiscal year.
  8. FY2023-Q3AdvancedAnnual report

    「During the cumulative third quarter of the current fiscal year, stock acquisition rights were exercised, increasing both share capital and capital surplus by ¥20.661 million.」

    The exercise of stock acquisition rights during the cumulative third quarter of the current fiscal year increased both share capital and capital surplus by ¥20.661 million.
  9. FY2023-Q2AdvancedAnnual report

    「Proceeds from the issuance of new shares upon exercise of stock acquisition rights: ¥29.258 million」

    During the cumulative second quarter of the current fiscal year, 151,200 shares were issued through the exercise of stock acquisition rights, resulting in additional funds raised.
  10. FY2023-Q1AdvancedAnnual report

    「1 July 2022–30 September 2022 86,100 16,287,200 6,085 1,859,193 6,085 3,515,219」

    During the quarter, 86,100 shares were issued through the exercise of stock options, increasing both share capital and capital reserves by ¥6.085 million.
  11. FY2022AdvancedAnnual report

    「Proceeds from the issuance of shares through the listing and exercise of stock options: ¥3.481986 billion (¥1.5 billion in the previous fiscal year)」

    The funding raised through the listing-related public offering and third-party allotment, together with proceeds from the issuance of shares upon exercise of stock options, is described.
  12. FY2022-Q3AdvancedAnnual report

    「In connection with the secondary offering of the company's shares through an over-allotment, with 26 January 2022 as the payment date, 388,900 new shares were issued through a third-party allotment, increasing both share capital and capital surplus by ¥252.240 million.」

    Following the listing and public offering, a third-party allotment related to the over-allotment was conducted, resulting in additional capital raised.
  13. FY2022-Q2AchievedAnnual report

    「The company was listed on the Tokyo Stock Exchange Mothers market on 24 December 2021. In connection with the listing, the issuance of 2,291,000 new shares through a public offering, with 23 December 2021 as the payment date, increased both share capital and capital surplus by ¥1.485942 billion.」

    The listing and public offering were completed on 24 December 2021, increasing share capital and capital surplus.
Moved together

"Use of a clinical trial system implementing blockchain technology" moved the same way as this thread, in the same document, in 7 of its 13 moves.

775555★123456
  1. ★This thread
  2. 1Use of a clinical trial system implementing blockchain technology7×
  3. 2Provision of a General-Purpose Clinical Trial System and a Machine-Learning-Based Automated Analysis System7×
  4. 3Regulatory approval for a digital therapeutic app for insomnia and preparations for insurance reimbursement5×
  5. 4Securing a Proof of Concept for an Advance Care Planning Support App5×
  6. 5Stabilizing Platform Revenue by Increasing the Number of Companies That Continue to Use the Platform5×
  7. 6Increase in Business Revenue and Narrower Losses5×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Susmed's next results are scheduled for 2026-11-06. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.